Katja Dicke, Vasileios Dervenis, Axel Hauschild, Thomas Dirschka
{"title":"[1例90岁妇女转移性默克尔细胞癌的局部肿瘤控制]。","authors":"Katja Dicke, Vasileios Dervenis, Axel Hauschild, Thomas Dirschka","doi":"10.1007/s00105-021-04799-0","DOIUrl":null,"url":null,"abstract":"<p><p>Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer. Many people suffer early local recurrences and distant metastases. The anti-PDL1 (PDL1: programmed death ligand 1) antibody avelumab has been approved as first-line treatment for advanced MCC in Europe. It is also an alternative treatment for old and multimorbid patients.</p>","PeriodicalId":12970,"journal":{"name":"Hautarzt","volume":"72 12","pages":"1090-1093"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00105-021-04799-0","citationCount":"0","resultStr":"{\"title\":\"[Local tumor control of metastatic Merkel cell carcinoma in a 90-year-old woman].\",\"authors\":\"Katja Dicke, Vasileios Dervenis, Axel Hauschild, Thomas Dirschka\",\"doi\":\"10.1007/s00105-021-04799-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer. Many people suffer early local recurrences and distant metastases. The anti-PDL1 (PDL1: programmed death ligand 1) antibody avelumab has been approved as first-line treatment for advanced MCC in Europe. It is also an alternative treatment for old and multimorbid patients.</p>\",\"PeriodicalId\":12970,\"journal\":{\"name\":\"Hautarzt\",\"volume\":\"72 12\",\"pages\":\"1090-1093\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s00105-021-04799-0\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hautarzt\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00105-021-04799-0\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hautarzt","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00105-021-04799-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
[Local tumor control of metastatic Merkel cell carcinoma in a 90-year-old woman].
Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer. Many people suffer early local recurrences and distant metastases. The anti-PDL1 (PDL1: programmed death ligand 1) antibody avelumab has been approved as first-line treatment for advanced MCC in Europe. It is also an alternative treatment for old and multimorbid patients.
期刊介绍:
Der Hautarzt is an internationally recognized journal informing all dermatologists working in practical or clinical environments about important developments in the field of dermatology including allergology, venereology and related areas.
Comprehensive reviews on a specific topical issue focus on providing evidenced based information on diagnostics and therapy.
Freely submitted original papers allow the presentation of important clinical studies and serve the scientific exchange.
Case reports feature interesting cases and aim at optimizing diagnostic and therapeutic strategies.
Review articles under the rubric "Continuing Medical Education" present verified results of scientific research and their integration into daily practice.